Category: ECMOCARD study

Critical care & ECMO in the era of COVID-19: why data matters

Critical care & ECMO in the era of COVID-19: why data matters! ELSO webinar, moderated by Dr. Robert Bartlett & Matt Paden, highlighting the current research underway focused on better understanding the impact of COVID-19, and the role of extracorporeal support and ICU care in patients with SARS-CoV-2 Coronavirus infection. Topics & speakers:
ELSO Registry and the live dashboard for COVID-19 Cases: Matt Paden & Ryan Barbaro
EuroELSO Survey on ECLS in COVID-19, Roberto Lorusso & Jan Bělohlávek
COVID-Critical Care Consortium, John Fraser & Heidi Dalton

Here full replay!

… and some slides:

Barbaro R.: We always know data matters! since H1N1 pandemic: now, more than 10 years later, COVID- 19 presented uncertainty & dynamic understanding, but thanks to community data soon start arriving, through:
ELSO Registry COVID-19 addendum and live dashboard
COVID critical care consortium
EuroELSO survey on ECMO in COVID-19

Lorusso R.: with @jan_belohlavek sharing (preliminary) data but really interesting insights from EuroECMO COVID, the scientific “adventure” of EuroELSO survey, amazing collection of data in really short ime, thanks to EuroELSO & collaborative centers.

Fraser J.: presenting COVID critical care consortium, global collaboration of more than 330 hospital across 50 countries, 1021 patients enrolled to date, aimed to characterize COVID-19 ICU pts, & its subgroups: we need data to get whole picture!

And please take the ongoing related surveys, ie neonatal and pediatric ICU & ECMO survey http://bit.ly/3d7MSmR aimed to acquire basic informations on neonates & pediatric SARS-CoV-2 Coronavirus patients requiring ICU admission/ECMO, or the ethics ECMO & pandemis survey.

ECMOCARD study, the story

The ECMOCARD Study first steps, trying to understand provide best care to COVID-19 patients who need critical care in ICU, from local outbreaks of Novel Coronavirus, to global pandemics of SARS-CoV-2. December, 26 2019: 4 unusual cases of pneumonia reported at HICWH Hospital in Wuhan, China; on January, 21 2020, first draft: ExtraCorporeal Membrane Oxygenation for 2019 WUhan CORonavirus Infection The ECMOWUCOR Observational trial, with study protocol in Chinese, Korean and Japanese one week later. At the end of January, ECMOWUCOR has been linked with SPRINT-SARI, Short PeRiod IncideNce sTudy of Severe Acute Respiratory Infection, & ISARIC, International Severe Acute Respiratory and Emerging Infection Consortium. On February, 4 2020, study title & acronym changed to ECMOCARD, ExtraCOrporeal Membrane, Oxygenation for novel Coronavlrus Acute Respiratory Disease… Work is in progress!

Collaboration mandatory: join & support ECMOCARD Study involving (to date):
43 Countries
6 Continents
286 Collaborative Centers
15 Recruiting Centers
with 265 enrolled Patients
All Trial Documents available here.
Additional info & graphics available.
Any question?? send email to ECMOCARD@ELSO.org

ECMOCARD study update

In a time of global crisis, global collaboration is essential: join & support ECMOCARD Study: how to provide best care to COVID-19 patients who need critical care in ICU? In the pictures, some of the international collaborators of ECMOCARD & updated active sites map!
All ECMOCARD Trial Documents available on the ELSO website
Any question?? send email to ECMOCARD@ELSO.org

Support & join ECMOCARD!

A global crisis needs a global response and global collaboration. In an unknown disease, ECMOCARD Study Group is coordinating with 26 countries across 4 continents to share data real-time.
With these data, we will use Artificial Intelligence to produce machine learning and feed back decision support to clincians who are currently “driving blindfold” in this entirely new and poorly understood condition.
Our best current asset is shared experience and global data to guide treatment today and tomorrow. But research needs to be supported!

Here a letter to the Political Leaders of Australia, signed by Professor John Fraser, Professor Robert Bartlett and by by all the regional Leads of the study (full list in the dedicated picture).
“The Covid-19 pandemic is an unprecedented global situation. The WHO calculates that between 60 and 80 per cent of the world population will be infected. This will place an overwhelming burden on hospitals in general, but specifically on intensive care resources. Never before have we seen this disease, nor its magnitude. We have no data on how best to care for our patients – specifically your parents. Without data, we are driving blindfold at 100 Km/h – with your relatives ir the vehicle.
Australian medical leaders realised the urgent necessity to gather key treatment information They stood up to this challenge – and created “ECMOCARD ” – the only global study to gather data or the ICU management of the sickest and most vulnerable patients. It is a great example of the globa medical community working as one- for the good of the global patients.
In representing the global ICU community, we respectfully and humbly ask the Australiar Government to align themselves with their medical leaders and take the leap. Support of the ECMOCARD global collaboration can assist the global community.
Australian Political Leaders should stand shoulder to shoulder with their Medical Leaders – for the sake of us all.

In these pictures, a list of the International ECMOCARD Study regional Leads (all of the have co-signed the letter), and a map with the active sites: the list is continuously updated, as more and more centers, in more Countries, are being involved, and join the study group.

We currently have 104 collaborating centres, and a further 7 sites anticipated to come on board in the near future. This is a fantastic effort on behalf of all collaborating sites and speaks volumes of the importance and clinical relevance of the data we are collecting (Sites map is superimposed to the online dashboard for tracking worldwide spread of the Coronavirus has been built & is regularly updated by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University; the map is freely available and constantly updated link).

Recently Professor John Fraser released an interview to Norman Swan for ABC’s Health Report and, discussing how intensive care specialists will deal with the influx of patients with SARS-CoV-2 infection. “We’ve got a global responsibility for our global community,” Professor Fraser said. Details about interview & full video here.

Prof. Bartlett on ECMOCARD

About the ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease ECMOCARD study, Professor Robert Bartlett, writes:”… our most important weapon in this crisis is data to predict and plan – on a global scale… a global problem needs global collaboration”. Here some words by Professor John Fraser, President of the Asia Pacific ELSO Chapter APELSO, introducing the study.
“Colleagues
As President of the Asia Pacific ELSO, I write to express my gratitude for all the work and collaboration from our brothers and sisters during this time of pandemic.
At times of global crisis, this is where teams show their strength. We have now more than. 50 centres in 20+ countries. over 4 continents that have signed up for the ECMOCARD study. Each night more centres are contacting us to join to work together; innovators and trailblazers that have come before us have given us the skills to hopefully be able to help the most critically unwell. It is in this environment that I am delighted that the father of #ECMO, Prof. Bob Bartlett has written to congratulate the ECMOCARD on the global collaboration we have created. Because a global crisis needs global collaboration for a global solution.
With Best wishes and thanks”
John
Attached, full text of Professor Bartlett letter.

ECMOCARD study

ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease ECMOCARD study is an multi-centre International study, conducted in all collaborating hospitals/ICU-based research networks in Asia, Australia & New Zealand (APELSO in collaboration with centres within the SPRINT-SARI and ISARIC Networks), and Europe, in COVID-19 patients requiringadmission to to ICU, Mechanical Ventilation &/or ECMO, to characterize:
incidence of ICU admission, need for non-invasive/invasive MV and ECMO 
risk factors, clinical features and severity of respiratory failure 
ECMO technical characteristics & duration of the run 
complications and ICU/Hospital survival 
requirements/time for approvals in participating network regions.

Aim is to recruit all eligible patients at each study location; patients will be studied specifically focusing on collecting data on MV, ECMO, main therapies (includinvasoactives, hypoxaemia rescue therapies, RRT), antibiotics/antivirals, adjunctive therapies, ie immunomodulators, corticosteroids, short-term outcomes.

Inclusion criteria

Laboratory-confirmed COVID-19 infection by real-time PCR and/or next-generation sequencing
Admission to an ICU

Exclusion criteria

MV for other concomitant causes 
ECMO for other concomitant causes 

Coronavirus

Family of RNA viruses which may infect mammals and birds, with 6 species known to cause human disease; 2 strains, the severe acute respiratory syndrome coronavirus SARS-CoV and Middle East respiratory syndrome coronavirus MERS-CoV have caused more serious, sometimes fatal, respiratory illnesses (reported mortality respectively 10% & 37%).

SARS-CoV-2 & COVID-19

In late December, 2019, in Wuhan, Hubei, China, new respiratory syndrome emerged with clinical signs resembling viral pneumonia and person-to-person transmission; analysis from lower respiratory tract samples corroborated emergence of novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 SARSCoV-2, causing  COrona VIrus Disease 2019 (COVID-19).